Showing 6221-6230 of 9536 results for "".
- ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Awardhttps://practicaldermatology.com/news/zoryve-wins-2025-allure-best-of-beauty-breakthrough-award/2483410/Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accol
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release